219 related articles for article (PubMed ID: 23614566)
41. Cytochrome P450 2D6 polymorphism and character traits.
Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
[TBL] [Abstract][Full Text] [Related]
42. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.
Snider NT; Sikora MJ; Sridar C; Feuerstein TJ; Rae JM; Hollenberg PF
J Pharmacol Exp Ther; 2008 Nov; 327(2):538-45. PubMed ID: 18698000
[TBL] [Abstract][Full Text] [Related]
43. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
44. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.
Vuong C; Xie LH; Potter BM; Zhang J; Zhang P; Duan D; Nolan CK; Sciotti RJ; Zottig VE; Nanayakkara NP; Tekwani BL; Walker LA; Smith PL; Paris RM; Read LT; Li Q; Pybus BS; Sousa JC; Reichard GA; Smith B; Marcsisin SR
Antimicrob Agents Chemother; 2015 Jul; 59(7):3864-9. PubMed ID: 25870069
[TBL] [Abstract][Full Text] [Related]
45. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
46. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
47. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
48. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
49. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
50. Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10.
Kong LM; Qian MR; Hu HH; Xu SY; Yu LS; Jiang HD; Chen SQ; Zeng S
Pharmazie; 2012 May; 67(5):440-7. PubMed ID: 22764579
[TBL] [Abstract][Full Text] [Related]
51. Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation.
Geier M; Braun A; Fladischer P; Stepniak P; Rudroff F; Hametner C; Mihovilovic MD; Glieder A
FEBS J; 2013 Jul; 280(13):3094-108. PubMed ID: 23552177
[TBL] [Abstract][Full Text] [Related]
52. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
53. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
Yu AM; Idle JR; Krausz KW; Küpfer A; Gonzalez FJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):315-22. PubMed ID: 12649384
[TBL] [Abstract][Full Text] [Related]
54. Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice.
Pan X; Jeong H
Mol Pharmacol; 2015 Jul; 88(1):106-12. PubMed ID: 25943116
[TBL] [Abstract][Full Text] [Related]
55. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
56. Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
DeVane CL; Markowitz JS; Carson SW; Boulton DW; Gill HS; Nahas Z; Risch SC
J Clin Psychopharmacol; 2000 Jun; 20(3):347-9. PubMed ID: 10831022
[TBL] [Abstract][Full Text] [Related]
57. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
58. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
59. Cytochrome P
Dhuya M; Pal MM; Hazra A; Chatterjee S; Gogtay N
Indian J Pharmacol; 2020; 52(3):189-195. PubMed ID: 32874001
[TBL] [Abstract][Full Text] [Related]
60. Inter-individual variability of in vivo CYP2D6 activity in different genotypes.
Chiba K; Kato M; Ito T; Suwa T; Sugiyama Y
Drug Metab Pharmacokinet; 2012; 27(4):405-13. PubMed ID: 22277677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
